Sector Experts

Hugh Cleland

Roadmap Capital Inc.

Image: Hugh Cleland

Hugh Cleland, BA, CFA, is cofounder, CEO, president, CIO and principal portfolio manager of the Roadmap Innovation Fund I and the Roadmap Trust. He is also portfolio manager, through a subadvisory contract between Roadmap Capital and BluMont Capital, of the BluMont Innovation PE Strategy Fund. Cleland earned a bachelor's degree with honors from Harvard University, and his CFA designation in 2001. After graduating from Harvard, Cleland worked in the research department at Midland Walwyn Capital (subsequently Merrill Lynch Canada) as research associate to the senior telecommunications services analyst. From March 1998 to March 2001, Cleland worked at Interward Capital Corp., first as an analyst, and later as associate portfolio manager, specializing in technology equities. He was founding portfolio manager at Northern Rivers Capital Management, where he worked from May 2001 until Northern Rivers was acquired by BluMont Capital in February 2010. Together with Riadh Zine, he cofounded Roadmap Capital Inc. in August 2013.




Recent Interviews

Apply Market Savvy to Bear Market Debris; Uncover Biotech Treasures: Cleland and Ireland (3/20/14) Starting a new investment company and investing in very small biotechs can be a minefield. Because the business is fraught with bad science and liquidity traps, it takes insight and industry experience to ensure investment capital doesn't drop down a foxhole. Roadmap Capital CEO and Founder Hugh Cleland is in the process of negotiating the minefield now. In this interview with The Life Sciences Report, Cleland and Stephen Ireland, Roadmap Capital principal and healthcare partner, discuss five growth names with merit, plus two brief bonus picks.

Small-Cap Biotechs with Blockbuster Potential: Hugh Cleland (6/27/13) Canadian portfolio manager Hugh Cleland of BluMont Capital has chosen an interesting niche. He invests in stocks too small for mutual funds and major institutions, which allows him to get in on the ground floor and capture huge gains when the companies begin to mature. He actively participates in each company's destiny, much like a venture capitalist. In this interview with The Life Sciences Report, Cleland discusses his "core four" and tosses in a handful of speculative tiny-cap companies that investors with enthusiasm for diligence should investigate.

Applying the Venture Capital Model to Public Companies: Hugh Cleland (11/15/12) Hugh Cleland has been testing his theory that life sciences companies can be had cheaper as stocks than as private venture capital investments—and that theory has been working out for him quite well over the past two years. In this interview with The Life Sciences Report, Cleland, portfolio manager and executive vice president at Toronto-based BluMont Capital, talks about his best small- and micro-cap ideas and also shares the "core/farm team" approach that he takes in his smaller, more conventionally structured fund.

Recent Quotes

"BLU presented to our advisory board and came out as one of the favorites." (3/19/14) BELLUS Health Inc. - The Life Sciences Report Interview with Hugh Cleland More >

"CTH has made huge strides, including closing a financing of $7.3M getting funding from the Michael J. Fox Foundation." (6/27/13) Cynapsus Therapeutics Inc. - The Life Sciences Report Interview with Hugh Cleland More >

"I am revisiting VRS after having made money on it in the past." (6/27/13) Verisante Technology Inc. - The Life Sciences Report Interview with Hugh Cleland More >

"The Angelo VMS preliminary data has been excellent, and that suggests FDA approval is likely for VPT." (11/15/12) VentriPoint Inc. - The Life Sciences Report Interview with Hugh Cleland More >

"Financing will give investors even more confidence that LPTN will have the capital it needs." (11/15/12) Lpath Inc. - The Life Sciences Report Interview with Hugh Cleland More >

"CTH could very well be worth more than CA$200M in three to five years." (11/15/12) Cynapsus Therapeutics Inc. - The Life Sciences Report Interview with Hugh Cleland More >

"I consider VPT to be a low-risk/high-reward opportunity." (8/9/12) VentriPoint Inc. - The Life Sciences Report Interview with Hugh Cleland More >

"If CTH can raise the money it needs, I expect it will create shareholder value in the $100–300M range within two to three years." (8/9/12) Cynapsus Therapeutics Inc. - The Life Sciences Report Interview with Hugh Cleland More >



Due to permission requirements, not all quotes are shown.